Table 4.
Multivariate survival analyses in relation to PFS and OS when NLR ≤ 2.68
| Variables | PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI lower | 95% CI upper | P | HR | 95% CI lower | 95% CI upper | P | |
| Gender | ||||||||
| Female | 1 | 1 | ||||||
| Male | 1.689 | 0.689 | 4.143 | 0.252 | 1.396 | 0.600 | 3.252 | 0.439 |
| Age (years) | ||||||||
| <45 | 1 | 1 | ||||||
| 45–65 | 0.157 | 0.050 | 0.492 | 0.001 | 0.204 | 0.067 | 0.620 | 0.005 |
| 65–80 | 0.179 | 0.057 | 0.561 | 0.003 | 0.270 | 0.086 | 0.843 | 0.024 |
| ≥80 | 0.219 | 0.045 | 1.052 | 0.058 | 0.496 | 0.104 | 2.373 | 0.380 |
| Smoking | ||||||||
| Non-smoker | 1 | |||||||
| Smoker | 1.006 | 0.409 | 2.476 | 0.989 | 1.544 | 0.672 | 3.545 | 0.306 |
| Tumor stage | ||||||||
| I | 1 | 1 | ||||||
| II | 0.774 | 0.357 | 1.679 | 0.517 | 0.842 | 0.385 | 1.842 | 0.668 |
| III | 1.841 | 0.437 | 7.756 | 0.406 | 0.900 | 0.193 | 4.191 | 0.893 |
| IV | 0.847 | 0.366 | 1.961 | 0.699 | 0.865 | 0.381 | 1.962 | 0.728 |
| Node stage | ||||||||
| N0 | 1 | 1 | ||||||
| N1 | 1.334 | 0.423 | 4.200 | 0.623 | 1.167 | 0.371 | 3.668 | 0.792 |
| N2 | 0.991 | 0.406 | 2.417 | 0.984 | 0.596 | 0.242 | 1.472 | 0.262 |
| N3 | 0.900 | 0.318 | 2.546 | 0.843 | 0.339 | 0.107 | 1.078 | 0.067 |
| Metastasis stage | ||||||||
| M0 | 1 | 1 | ||||||
| M1a | 2.408 | 0.832 | 6.966 | 0.105 | 1.816 | 0.632 | 5.218 | 0.268 |
| M1b | 4.164 | 1.499 | 11.569 | 0.006 | 3.724 | 1.339 | 10.358 | 0.012 |
| Neutrophil (cells/ml) | ||||||||
| ≤3.41 × 109 | 1 | 1 | ||||||
| >3.41 × 109 | 1.211 | 0.692 | 2.120 | 0.503 | 1.087 | 0.607 | 1.947 | 0.779 |
| PLR | ||||||||
| ≤119.50 | 1 | 1 | ||||||
| >119.50 | 1.879 | 1.047 | 3.374 | 0.035 | 2.046 | 1.122 | 3.732 | 0.020 |
| CRP (mg/L) | ||||||||
| ≤10.4 | 1 | 1 | ||||||
| >10.4 | 2.786 | 1.374 | 5.648 | 0.004 | 3.014 | 1.490 | 6.099 | 0.002 |
CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; NLR, neutrophil to lymphocyte ratio; OS, overall survival; PFS, progression-free survival; PLR, platelet to lymphocyte ratio.